Type 2 Diabetes

Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using semaglutide therapy than when they are not using the drug, according to findings from a retrospective study.

Researchers found that women with hypertension who followed a very low-calorie ketogenic diet had lower systolic and diastolic blood pressure at 6 months than those who participated in intermittent fasting or had no dietary restrictions.

Glomerular hyperfiltration may increase CVD risks, including myocardial infarction and heart failure, for patients with type 2 diabetes, study data show.

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, according to data from a cohort study published in the Journal of Diabetes and Its Complications.

The prevalence of diabetes is increasing faster in some low-income countries than elsewhere in the world, generating concerns about health care infrastructure and access to treatment for people in those regions.

Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated insulin delivery system, according to findings from the SECURE-T2D trial.

Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio than those receiving comparators such as placebo or another therapy, researchers reported.

A randomized controlled trial demonstrated a significantly reduced incidence of type 2 diabetes among individuals with metabolic syndrome who received daily metformin with or without a Mediterranean diet intervention.

SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes compared with younger adults, according to findings from a systematic review and meta-analysis published in JAMA.

More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported in JAMA Network Open.